DDInter1771 DDInter1747
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Teriflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melatonin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Mephenytoin
Teriflunomide {u} may lead to a major life threatening interaction when taken with {v} Asparaginase Erwinia chrysanthemi
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Melatonin
Teriflunomide may lead to a major life threatening interaction when taken with Mephenytoin
Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi